within Pharmacolibrary.Drugs.ATC.N;

model N05AH53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.4166666666666667,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 1.0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013833333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Olanzapine and samidorphan is a fixed-dose combination drug consisting of olanzapine, an atypical antipsychotic used for the treatment of schizophrenia and bipolar I disorder, and samidorphan, an opioid receptor antagonist used to mitigate olanzapine-induced weight gain. The combination (marketed as Lybalvi) is approved for use in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult subjects after oral administration of olanzapine and samidorphan combination; values approximated from published prescribing information.</p><h4>References</h4><ol><li><p>Sun, L, et al., &amp; von Moltke, L (2019). Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan. <i>Clinical pharmacology in drug development</i> 8(4) 503–510. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.688&quot;>10.1002/cpdd.688</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30921503/&quot;>https://pubmed.ncbi.nlm.nih.gov/30921503</a></p></li><li><p>Sun, L, et al., &amp; von Moltke, L (2020). Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate. <i>Clinical drug investigation</i> 40(1) 55–64. DOI:<a href=&quot;https://doi.org/10.1007/s40261-019-00860-y&quot;>10.1007/s40261-019-00860-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31584140/&quot;>https://pubmed.ncbi.nlm.nih.gov/31584140</a></p></li><li><p>Sun, L, et al., &amp; Rowland Yeo, K (2021). Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination. <i>Clinical pharmacokinetics</i> 60(5) 637–647. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00969-w&quot;>10.1007/s40262-020-00969-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33313995/&quot;>https://pubmed.ncbi.nlm.nih.gov/33313995</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AH53;
